Literature DB >> 9131719

Side effects of nondepolarizing muscle relaxants: relationship to their antinicotinic and antimuscarinic actions.

E S Vizi1, B Lendvai.   

Abstract

Since acetylcholine (ACh) is the 'master key' to different subtypes of nicotinic and muscarinic receptors, and muscle relaxants (MRs) available in clinical practice are structurally related to it, MRs may exert their unwanted effects through inhibition of these receptors. Since the subunit composition of nicotinic ACh receptors (nAChRs) of pre- and/or postsynaptic location and the binding potency of MRs to these and muscarinic receptors are different, a search for selective muscle nAChR antagonists without or with less side effects seems to be promising and important for clinical practice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9131719     DOI: 10.1016/s0163-7258(96)00139-8

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  4 in total

1.  Block of postjunctional muscle-type acetylcholine receptors in vivo causes train-of-four fade in mice.

Authors:  M Nagashima; T Sasakawa; S J Schaller; J A J Martyn
Journal:  Br J Anaesth       Date:  2015-04-01       Impact factor: 9.166

2.  Train-of-four and tetanic fade are not always a prejunctional phenomenon as evaluated by toxins having highly specific pre- and postjunctional actions.

Authors:  Michio Nagashima; Shingo Yasuhara; J A Jeevendra Martyn
Journal:  Anesth Analg       Date:  2013-03-11       Impact factor: 5.108

3.  Physiologic-pharmacologic interpretation of the constants in the Hill equation for neuromuscular block: a hypothesis.

Authors:  Vladimir Nigrovic; Anton Amann
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-04       Impact factor: 2.745

4.  Competition between acetylcholine and a nondepolarizing muscle relaxant for binding to the postsynaptic receptors at the motor end plate: simulation of twitch strength and neuromuscular block.

Authors:  Vladimir Nigrovic; Anton Amann
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.